

For Health Professionals Who Care for People with Cancer

Inside This Issue:

Editor's Choice

New Programs

- **UGIAVFRU** Treatment of Advanced Colorectal Cancer using Fruquintinib
- **GIRNACOX** Neoadjuvant Treatment for Locally Advanced Rectal Cancer using Oxaliplatin and Capecitabine
- **GIRNAFFOX** Neoadjuvant Treatment for Rectal Cancer using Oxaliplatin, Fluorouracil and Leucovorin
- **GIRLCRT** Combined Modality Therapy for High-Risk Rectal Carcinoma using Capecitabine and Radiation Therapy
- **HNLADOCRT** Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck with Concurrent Weekly Docetaxel and Radiation
- **LUAJALE** Adjuvant Treatment of Resected ALK-Positive Non-Small Cell Lung Cancer with Alectinib
- **ULYWMIBRU** Treatment of Waldenström Macroglobulinemia or Lymphoplasmacytic Lymphoma using Ibrutinib

Dose Banding: capecitabine, temozolomide

Practice Standards and Policies

- Influenza Vaccine Recommendations
- Transitioning from Reference Biologics to Biosimilars

Drug Update

IV Bag Size Selection: vincristine, vinorelbine

Cancer Drug Manual®

New fruquintinib **Revised** azacitidine, gemcitabine

Chemotherapy Preparation and Stability Chart docetaxel, gemcitabine, vincristine, vinorelbine

Continuing Education

Family Practice Oncology Network

Benefit Drug List

New UGIAVFRU, GIRLCRT, GIRNACOX, GIRNAFFOX, HNLADOCRT, LUAJALE, ULYWMIBRU

Revised GIRAJCOX, GIRAJFFOX

Protocols, PPPOs and Patient Handouts

New GI UGIAVFRU, GIRLCRT, GIRNACOX, GIRNAFFOX
HN HNLADOCRT LU LUAJALE LY ULYWMIBRU

Revised BR BRAJCAP, BRAVCAP, BRAVLCAP, BRAVTCAP, UBRAVTTCAP CN CNAJ12TZRT, CNAJ TZRT, CNELTZRT, CNTEM60, CNTEMOZ, CNTEMOZMD, CNTMZETO
GI GIAJCAP, GIAJCAPOX, GIAVCAP, GIAVCRT, GIAVTZCAP, GIBAJCAP, GICAPIRI, GICAPOX, GICART, GICIRB, GICPART, GIFFOXPAN, GIGAJCOX, GIGAJCPRT, GIGAVCC, GIGAVCCT, GIGAVCOX, GIGAVCOXN, GIGAVCOXP, GIGAVCOXT, GIGAVPCOXT, GIGECC, GIPAIGCAP, GIPAVCAP, GIRAJCOX, GIRCAP, GIRAJFFOX, GIRCRT, GIRINFRT HN HNAVCAP, HNNAVCAP LU LUVALE, LUAVBRI, LUAVCRIZ, LUAVCRIZF, LUAVLOR LY LYBENDO, LYCLLIV, LYDARCBDF, LYDHAPR, LYGDP, LYGDPO, LYGDPR, LYGEMOXPEG, LYHDMRTEM, LYOBCHLOR, LYPRA, LYTEM, ULYWMZANU SM SMAVTMZ

Resources and Contact Information

Editor's Choice

New Programs

BC Cancer Provincial Systemic Therapy has approved the following new treatment programs effective 01 November 2025. Full details of all treatment programs are available in the [Chemotherapy Protocols](#) section of the BC Cancer website.

Gastrointestinal

Fruquintinib for Treatment of Advanced Colorectal Cancer (UGIAVFRU) – The BC Cancer Gastrointestinal Tumour Group is introducing fruquintinib, an oral VEGF receptor inhibitor, for the treatment of unresectable or metastatic colorectal adenocarcinoma or adenocarcinoma of the appendix or small bowel.

Editor's Choice

Treatment eligibility includes prior treatment in the advanced setting as outlined in the treatment protocol. BC Cancer Compassionate Access Program (CAP) approval is required.

The randomized, placebo-controlled, phase III FRESCO-2 trial was undertaken in patients with metastatic colorectal cancer who had received several prior lines of therapy in the advanced setting.^{1,2} The trial demonstrated that treatment with fruquintinib plus best supportive care (BSC) resulted in statistically significant and clinically meaningful improvements in overall survival and progression-free survival compared with placebo plus BSC. Compared to placebo, fruquintinib was associated with a higher frequency of grade 3 or greater adverse effects, including hypertension, asthenia and hand-foot syndrome. Overall, the safety profile of fruquintinib was consistent with the known safety of VEGF inhibitors.

Oxaliplatin and Fluoropyrimidine for Neoadjuvant Treatment of Locally Advanced Rectal Cancer (GIRNACOX, GIRNAFFOX) – The BC Cancer Gastrointestinal Tumour Group is streamlining treatment protocols used for patients with locally advanced rectal cancer. Patients receiving adjuvant therapy following surgical resection will continue to receive oxaliplatin and fluoropyrimidine chemotherapy using GIRAJCOX and GIRAJFFOX. Patients receiving total neoadjuvant therapy, which entails both chemotherapy and radiation therapy before surgical resection, will receive oxaliplatin and fluoropyrimidine chemotherapy using the new GIRNACOX and GIRNAFFOX protocols. For the capecitabine chemoradiation component of treatment, GIRLCRT will replace GIRCRT for all new patients; it may be used neoadjuvantly or adjuvantly (**GIRLCRT: Combined Modality Therapy for High-Risk Rectal Carcinoma using Capecitabine and Radiation Therapy**).

Head and Neck

Weekly Docetaxel and Concurrent Radiation for Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNLADOCT) – The BC Cancer Head and Neck Tumour Group is implementing weekly docetaxel with concurrent radiation for patients with non-metastatic, locally advanced squamous cell carcinoma of the head and neck who are suitable for radical radiation. This treatment protocol provides the option of docetaxel as a radiosensitizer for cisplatin-ineligible patients. In a phase III randomized trial, cisplatin-ineligible patients with locally advanced head and neck squamous cell carcinoma were randomized to radiation alone or radiation with concurrent weekly docetaxel.³ Radiotherapy with concurrent docetaxel demonstrated improved disease-free survival and overall survival compared radiotherapy alone.

Lung

Alectinib for Adjuvant Treatment of Resected ALK-Positive Non-Small Cell Lung Cancer (LUAJALE) – The BC Cancer Lung Tumour Group is implementing treatment with alectinib for patients with ALK-positive non-small cell lung cancer (NSCLC) in the curative setting. Alectinib is initiated following complete resection or adjuvant platinum-based chemotherapy and is continued for two years. Full eligibility details including disease staging are available in the treatment protocol.

The open-label, randomized, controlled phase III ALINA trial compared adjuvant treatment with alectinib to platinum-based chemotherapy in patients who had complete resection of ALK-positive NSCLC.^{4,5} Alectinib resulted in a significant reduction in the risk of disease recurrence. In addition to the benefit in disease-free survival (DFS), alectinib was also associated with a clinically meaningful benefit in central nervous system DFS as compared with chemotherapy. Toxicity was consistent with prior studies with alectinib, and no new safety signals were noted.

Editor's Choice

Ibrutinib for Treatment of Waldenström Macroglobulinemia or Lymphoplasmacytic Lymphoma (ULYWMI BRU) – The BC Cancer Lymphoma Tumour Group is implementing treatment with ibrutinib for patients with relapsed or refractory Waldenström macroglobulinemia (WM) or lymphoplasmacytic lymphoma (LPL) requiring therapy for symptomatic disease. Patients must have received at least one prior systemic therapy to be eligible. Patients with relapsed or refractory WM or LPL are also eligible for treatment with zanubrutinib (ULYWMI ZANU). BC Cancer Compassionate Access Program (CAP) approval is required.

The single-arm substudy of the phase III iNNOVATE trial assessed ibrutinib monotherapy in patients with WM failing to achieve a response to rituximab. Ibrutinib demonstrated efficacy in terms of median overall survival and progression-free survival.^{6,7} The randomized, controlled phase III ASPEN trial compared ibrutinib to zanubrutinib, and found both ibrutinib and zanubrutinib were highly effective in the treatment of WM and LPL. The incidence and severity of many toxicities, particularly cardiovascular toxicity, were higher with ibrutinib than with zanubrutinib.⁸

References:

1. CADTH Reimbursement Recommendation. Fruquintinib (Fruzaqla®). *Canadian Journal of Health Technologies* 2024;4(12):1-28. <https://doi.org/10.51731/cjht.2024.1042>
2. Dasari A, Lonardi S, Garcia-Carbonero R, et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. *Lancet* 2023;402:41-53. [https://doi.org/10.1016/S0140-6736\(23\)00772-9](https://doi.org/10.1016/S0140-6736(23)00772-9)
3. Patil VM, Noronha V, Menon N, et al. Results of phase III randomized trial for use of docetaxel as a radiosensitizer in patients with head and neck cancer, unsuitable for cisplatin-based chemoradiation. *J Clin Oncol* 2023;41(13):2350-2361. <https://doi.org/10.1200/JCO.22.00980>
4. CADTH Reimbursement Recommendation. Alectinib (Alecensaro®). *Canadian Journal of Health Technologies* 2024;4(11): 1-24. <https://doi.org/10.51731/cjht.2024.1027>
5. Wu YL, Dziadziuszko R, Ahn JS, et al. Alectinib in resected ALK-positive non-small-cell lung cancer. *N Engl J Med* 2024;390(14):1265-1276. <https://doi.org/10.1056/NEJMoa2310532>
6. CADTH Reimbursement Recommendation. Ibrutinib (Imbruvica®). *Canadian Journal of Health Technologies* 2024;4(1):1-27. <https://doi.org/10.51731/cjht.2024.821>
7. Trotman J, Buske C, Tedeschi A, et al. Single-agent ibrutinib for rituximab-refractory Waldenström macroglobulinemia: final analysis of the substudy of the phase III Innovate trial. *Clin Cancer Res* 2021;27(21):5793-5800. <https://doi.org/10.1158/1078-0432.CCR-21-1497>
8. Tam CS, Opat S, D'Sa S, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. *Blood* 2020;136(18):2038-2050. <https://doi.org/10.1182/blood.2020066844>

Dose Banding: Capecitabine, Temozolomide

As part of the continued dose banding rollout at BC Cancer:

- standardized dose bands for **capecitabine** and **temozolomide** have been integrated into all protocols, provincial preprinted orders (PPPOs) and the Cerner system
- the dose banding expansion will continue with nivolumab and ipilimumab on 01 December 2025
- Systemic Therapy **Procedure III-140: Management of Dose Banded Cancer Drug Treatments**, available on the [SHOP](#) BC Cancer page, continues to be updated to reflect the drugs approved for dose banding

Practice Standards and Policies

All Systemic Therapy policies are on the [Shared Health Organizations Portal \(SHOP\)](#) BC Cancer page.

Updated: Influenza Vaccine Recommendations

The **BC Cancer Influenza Vaccine Recommendations for Adults with Cancer** have been updated for the 2025-2026 influenza season. They are available on the BC Cancer website in the [Supportive Care](#) section of the Cancer Management Manual and on the [Supportive Care](#) page in the Chemotherapy Protocols section.

As in the previous flu season, patients should be offered an age-appropriate **inactivated influenza vaccine**. The trivalent inactivated influenza vaccine is recommended for adults under 65 years of age, while the adjuvanted trivalent inactivated influenza vaccine is recommended for all adults 65 years of age and older. Updates include recommendations for patients receiving B cell-depleting therapies and for patients post-HSCT/CART therapy.

Transitioning from Reference Biologics to Biosimilars

Long-term clinical evidence supports comparability between the reference biologics trastuzumab (HERCEPTIN) and bevacizumab (AVASTIN) and their biosimilars. As such, BC Cancer will be transitioning all remaining patients being treated with one of these two reference biologics to their corresponding biosimilar on or after 01 December 2025.

Providers with patients on HERCEPTIN or AVASTIN are encouraged to speak with their patients about this transition ahead of 01 December 2025. This will prevent any treatment delays if patients have questions about the transition.

Staff can leverage the newly developed patient fact sheet if patients have questions about the transition. The [Transitioning to a Biosimilar Drug](#) fact sheet can be found in the Biosimilar Drugs section of the BC Cancer website.

After 01 December 2025:

- Access to HERCEPTIN and AVASTIN will require BC Cancer Compassionate Access Program (CAP) approval. Approval will only be granted for safety or significant adverse event reasons.
- CON sites will have a 6-month transition period to use up old inventory of the reference biologics. New inventory will not be reimbursed past the transition date without BC Cancer approval.

There will be no changes to BC Cancer Cerner PowerPlans or PPPOs.

Questions can be sent to ProvincialSystemicOffice@bccancer.bc.ca.

Drug Update

IV Bag Size Selection: Vincristine, Vinorelbine

The **IV Bag Size Selection** table has been updated. A 25 mL bag size has been added for both vincristine and vinorelbine, and the dose range has been defined for the 25 mL and 50 mL bags. The **IV Bag Size and Vial Selection** resource is available in the [Cancer Drug Manual](#)® on the BC Cancer website.

Cancer Drug Manual®

All documents are available in the [Cancer Drug Manual](#)® on the BC Cancer website.

New CDM Documents

The **Fruquintinib Monograph** and **Patient Handout** have been developed with expert review provided by Dr. Theresa Chan (medical oncologist, BC Cancer Gastrointestinal Tumour Group) and Robert Tillmanns (tumour group pharmacist, BC Cancer Provincial Pharmacy). Fruquintinib is an orally administered tyrosine kinase inhibitor that selectively targets VEGF receptors 1, 2 and 3. It is used in the treatment of metastatic colorectal cancer. The usual dose is 5 mg once daily for 21 consecutive days in a 28-day cycle, following BC Cancer Protocol UGIAVFRU.

Highlights from these documents include:

- hypertension usually occurs in the first cycle; pre-existing hypertension should be adequately controlled prior to starting treatment
- fruquintinib is not recommended in patients with recent history of thromboembolic event, stroke, or ischemic attack
- impaired wound healing is reported; consider holding fruquintinib for at least two weeks before and after surgery to allow for adequate wound healing

Fruquintinib has been added to the **Auxiliary Label List** and was evaluated for the **BC Health Authorities Provincial Hazardous Drug List**.

Revised CDM Documents

Azacitidine Monograph

Side Effects table: added differentiation syndrome and necrotizing fasciitis

Side Effects paragraphs: added new paragraph for differentiation syndrome

Solution Preparation and Compatibility: added information about particulates

Parenteral Administration table: added information about resuspending syringe contents prior to administration to align with Chemotherapy Preparation and Stability Chart

Dosage Guidelines: updated dosage in renal failure

Gemcitabine Monograph

Uses: updated Health Canada-approved indications

Special Precautions: updated Mutagenicity, Fertility, and Pregnancy

Dosage Guidelines: updated dosing with concurrent radiation

Chemotherapy Preparation and Stability Chart

Docetaxel: updated recommended bag size range (to 25-500 mL) to align with bag size selection table

Gemcitabine: updated recommended bag size range (to 50-250 mL) to align with bag size selection table

Vincristine: updated recommended bag size range (to 25-50 mL) to align with bag size selection table

Vinorelbine: updated recommended bag size range (to 25-50 mL) to align with bag size selection table

Continuing Education

Family Practice Oncology Network

The Family Practice Oncology Network (FPON) is pleased to announce a webinar on **Recognizing Hematologic Malignancies in Primary Care** with Dr. Leslie Zypchen. The webinar is 0800-0900h on Thursday 20 November 2025, as part of the complimentary accredited FPON webcasts.

By the end of the session, participants will be able to:

- Describe clonal hematopoiesis as a precursor to hematologic malignancies and recognize its prevalence in primary care
- Review an approach to unexplained cytopenias
- Identify clinical features that should prompt referral to a hematologist
- Differentiate between monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma

For more information and link to registration, visit:

[UBC CPD | FPON Webinar: Recognizing Hematologic Malignancies in Primary Care](#)

Benefit Drug List

New Programs

The following treatment programs have been added to the BC Cancer [Benefit Drug List](#) effective 01 November 2025:

Protocol Title	Protocol Code	Benefit Status
Treatment of Advanced Colorectal Cancer using Fruquintinib	UGIAVFRU	Restricted
Combined Modality Therapy for High-Risk Rectal Carcinoma using Capecitabine and Radiation Therapy	GIRLCRT	Class I
Neoadjuvant Treatment for Locally Advanced Rectal Cancer using Oxaliplatin and Capecitabine	GIRNACOX	Class I
Neoadjuvant Treatment for Rectal Cancer using Oxaliplatin , Fluorouracil and Leucovorin	GIRNAFFOX	Class I
Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck with Concurrent Weekly Docetaxel and Radiation	HNLADOCRT	Class I
Adjuvant Treatment of Resected ALK-Positive Non-Small Cell Lung Cancer with Alectinib	LUAJALE	Class I
Treatment of Waldenström Macroglobulinemia or Lymphoplasmacytic Lymphoma (LPL) using Ibrutinib	ULYWMIBRU	Restricted

Revised Programs

The following treatment programs have been revised on the BC Cancer [Benefit Drug List](#) effective 01 November 2025:

Protocol Title	Protocol Code	Benefit Status
Adjuvant Treatment for Stage III Rectal Cancer using Oxaliplatin and Capecitabine ✓ Protocol title updated	GIRAJCOX	Class I
Adjuvant Treatment for Stage III Rectal Cancer using Oxaliplatin , Fluorouracil and Leucovorin ✓ Protocol title updated	GIRAJFFOX	Class I

Highlights of New & Revised Protocols, PPPOs and Patient Handouts

BC Cancer Treatment Protocols, Provincial Preprinted Orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below, with document revisions indicated in the respective columns. Protocol codes for treatment requiring BC Cancer Compassionate Access Program (CAP) approval are prefixed with the letter **U**.

NEW Protocols, PPPOs and Patient Handouts (*new documents checked* ☒)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
UGIAVFRU	Treatment of Advanced Colorectal Cancer using Fruquintinib	☒	☒	☐
GIRLCRT	Combined Modality Therapy for High-Risk Rectal Carcinoma using Capecitabine and Radiation Therapy	☒	☒	☐
GIRNACOX	Neoadjuvant Treatment for Locally Advanced Rectal Cancer using Oxaliplatin and Capecitabine	☒	☒	☐
GIRNAFFOX	Neoadjuvant Treatment for Rectal Cancer using Oxaliplatin, Fluorouracil and Leucovorin	☒	☒	☐
HNLADOCRT	Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck with Concurrent Weekly Docetaxel and Radiation	☒	☒	☐
LUAJALE	Adjuvant Treatment of Resected ALK-Positive Non-Small Cell Lung Cancer with Alectinib	☒	☒	☐
ULYWMBIRU	Treatment of Waldenström Macroglobulinemia or Lymphoplasmacytic Lymphoma (LPL) using Ibrutinib	☒	☒	☐

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
BR Breast				
BRAJCAP	Therapy of Adjuvant Breast Cancer using Capecitabine	<i>Dose banding added; Tests clarified; Contact Physician updated</i>	<i>Dose banding added; Tests clarified</i>	---
BRAVCAP	Therapy of Metastatic Breast Cancer using Capecitabine	<i>Dose banding added; Contact Physician and Tests updated; Eligibility clarified</i>	<i>Dose banding added; Tests updated</i>	---
BRAVLCAP	Therapy for Metastatic Breast Cancer using Capecitabine and Lapatinib	<i>Dose banding added; Tests updated</i>	<i>Dose banding added; Tests updated</i>	---
BRAVTCAP	Palliative Therapy for Metastatic Breast Cancer using Trastuzumab and Capecitabine	<i>Dose banding added; Tests clarified</i>	<i>Dose banding added; Tests clarified</i>	---

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
UBRAVTCAP	Palliative Therapy for Metastatic Breast Cancer using Trastuzumab, Tucatinib and Capecitabine	<i>Dose banding added; Tests and infusion time clarified</i>	<i>Dose banding added; Tests and infusion time clarified</i>	---
CN Neuro-Oncology				
CNAJ12TZRT	Concomitant (Dual Modality) and 12 Cycles of Adjuvant Temozolomide for Newly Diagnosed Malignant Gliomas with Radiation	<i>Dose banding added; Tests and Treatment clarified</i>	<i>Dose banding added; Treatment clarified</i>	---
CNAJ TZRT	Concomitant (Dual Modality) and Adjuvant Temozolomide for Newly Diagnosed Malignant Gliomas with Radiation	<i>Dose banding added; Tests and Treatment clarified</i>	<i>Dose banding added; Tests and Treatment clarified</i>	---
CNELTZRT	Treatment of Elderly Newly Diagnosed Glioma Patient with Concurrent and Adjuvant Temozolomide and Radiation Therapy	<i>Dose banding added; Tests and Treatment clarified</i>	<i>Dose banding added; Treatment clarified</i>	---
CNTEM60	Therapy for Newly Diagnosed Malignant Brain Tumours with MGMT Methylation in Elderly Patients using Temozolomide	<i>Dose banding added; Tests clarified</i>	<i>Dose banding added; Tests and Treatment clarified</i>	---
CNTEMOZ	Therapy for Malignant Brain Tumours using Temozolomide	<i>Dose banding added; Tests clarified</i>	<i>Dose banding added; Tests and Treatment clarified</i>	---
CNTEMOZMD	Therapy for Malignant Brain Tumours using Metronomic Dosing of Temozolomide	<i>Dose banding added; Tests clarified</i>	<i>Dose banding added; Tests and Treatment clarified</i>	---
CNTMZETO	Therapy for Recurrent Malignant Brain Tumours using Temozolomide and Etoposide	<i>Dose banding added; Tests and Treatment clarified</i>	<i>Dose banding added; Tests and Treatment clarified</i>	---
GI Gastrointestinal				
GIAJCAP	Adjuvant Therapy of Colon Cancer using Capecitabine	<i>Dose banding added</i>	<i>Dose banding added; Treatment clarified</i>	---
GIAJCAPOX	Adjuvant Combination Chemotherapy for Stage III and Stage IIB Colon Cancer using Oxaliplatin and Capecitabine	<i>Dose banding added; Exclusions and Premedications clarified</i>	<i>Dose banding added; Treatment clarified</i>	---
GIAVCAP	Palliative Therapy of Advanced Gastrointestinal Cancer using Capecitabine	<i>Dose banding added</i>	<i>Dose banding and page numbers added; Treatment clarified</i>	---

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
GIAVCRT	Combined Modality Therapy for Metastatic Rectal Carcinoma using Capecitabine and Radiation Therapy	<i>Dose banding added; creatinine clearance clarified</i>	<i>Dose banding added; Premedication section removed</i>	---
GIAVTZCAP	Palliative Therapy of Metastatic Neuroendocrine Cancer using Temozolomide and Capecitabine	<i>Dose banding added; temozolomide dose, tests and dose modifications clarified</i>	<i>Dose banding added; temozolomide dose and tests clarified</i>	---
GIBAJCAP	Adjuvant Therapy of Biliary Cancer using Capecitabine	<i>Dose banding added; creatinine clearance and Dose Modification clarified</i>	<i>Dose banding added; Premedications removed; Treatment clarified</i>	---
GICAPIRI	Palliative Combination Chemotherapy for Metastatic Colorectal or Biliary Tract Cancer using Irinotecan and Capecitabine in Patients Unsuitable for GIFOLFIRI	<i>Dose banding added; Cautions, Precautions and infusion time clarified</i>	<i>Dose banding added; infusion time and Treatment clarified</i>	---
GICAPOX	Palliative Combination Chemotherapy for Metastatic Colorectal or Biliary Tract Cancer using Oxaliplatin and Capecitabine	<i>Dose banding added; Exclusions and Premedications clarified</i>	<i>Dose banding added; Premedications and Treatment clarified</i>	---
GICART	Curative Combined Modality Therapy for Carcinoma of the Anal Canal using Mitomycin, Capecitabine and Radiation Therapy	<i>Dose banding added; Treatment clarified; Precautions updated</i>	<i>Dose banding added</i>	---
GICIRB	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Irinotecan, Bevacizumab and Capecitabine	---	<i>Capecitabine dose clarified</i>	---
GICPART	Curative Combined Modality Therapy for Carcinoma of the Anal Canal using Cisplatin, Capecitabine and Radiation Therapy	<i>Dose banding added; Treatment clarified</i>	<i>Dose banding added; Treatment, units and infusion duration clarified</i>	---
GIFFOXPAN	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Oxaliplatin, Fluorouracil, Leucovorin and Panitumumab	<i>Eligibility and Exclusions updated</i>	---	---
GIGAJCOX	Adjuvant Chemotherapy in Gastric Cancer Patients with D2 Resection (Node-Negative) or Ineligible for Adjuvant Chemoradiation using Oxaliplatin and Capecitabine	<i>Dose banding added; Exclusions and Premedications clarified</i>	<i>Dose banding added; Premedications and Treatment clarified; page numbers added</i>	---

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
GIGAJCPRT	Adjuvant Chemotherapy of Gastric Cancer Patients with Completely Resected Gastric Cancer using Cisplatin and Capecitabine and Radiation Therapy	<i>Dose banding added; Treatment and Dose Modification clarified</i>	<i>Dose banding added; infusion duration, Tests and units clarified</i>	---
GIGAVCC	Palliative Therapy of Metastatic or Locally Advanced Anal Squamous Cell Carcinoma using Cisplatin and Capecitabine	<i>Dose banding added; Treatment and Dose Modification clarified</i>	<i>Dose banding added; units, Treatment and infusion durations clarified</i>	---
GIGAVCCT	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma using Cisplatin, Capecitabine and Trastuzumab	<i>Dose banding added; Treatment and Dose Modifications clarified; TALLman lettering corrected</i>	<i>Dose banding added; infusion/observat ion/treatment durations and units clarified</i>	---
GIGAVCOX	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction or Esophageal Carcinoma using Capecitabine and Oxaliplatin	<i>Dose banding added; Exclusions and Treatment clarified; hyperlink added</i>	<i>Dose banding added; Treatment clarified</i>	---
GIGAVCOXN	First-Line Treatment of Locally Advanced or Metastatic Esophageal, Gastroesophageal or Gastric Cancer using Oxaliplatin, Capecitabine and Nivolumab	<i>Dose banding added; Exclusions, Cautions and Treatment clarified; hyperlinks updated</i>	<i>Dose banding added; Treatment clarified</i>	---
GIGAVCOXP	First-Line Treatment of Locally Advanced or Metastatic Gastroesophageal Cancer using Oxaliplatin, Capecitabine and Pembrolizumab	<i>Dose banding added; Exclusions, Cautions and Treatment clarified; hyperlink added</i>	<i>Dose banding added; Treatment clarified</i>	---
GIGAVCOXT	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma using Capecitabine, Oxaliplatin and Trastuzumab	<i>Dose banding added; Exclusions and Treatment clarified; TALLman lettering and hyperlink added</i>	<i>Dose banding added; Treatment clarified</i>	---
GIGAVPCOXT	Treatment of Advanced Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma using Pembrolizumab, Capecitabine, Oxaliplatin and Trastuzumab	<i>Dose banding added; Exclusions and Treatment clarified; hyperlink added</i>	<i>Dose banding added; Treatment clarified</i>	---
GIGECC	Perioperative Treatment of Resectable Adenocarcinoma of the Stomach, Gastroesophageal Junction or Lower 1/3 Esophagus using Epirubicin, Cisplatin and Capecitabine	<i>Dose banding added; Eligibility, Exclusions, Treatment and Dose Modifications clarified</i>	<i>Dose banding added; infusion duration and units clarified</i>	---
GIPAJGCAP	Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma using Capecitabine and Gemcitabine	<i>Dose banding added; Eligibility, Cautions and Exclusions clarified</i>	<i>Dose banding added; Treatment clarified</i>	---

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
GIPAVCAP	Second-Line Treatment of Metastatic or Unresectable Pancreatic Adenocarcinoma using Capecitabine	<i>Dose banding added; Eligibility and Tests clarified; Premedications updated to low emetogenic potential; hyperlink added</i>	<i>Dose banding added; Treatment and Tests clarified</i>	---
GIRAJCOX	Adjuvant or Neoadjuvant Combination Chemotherapy Treatment for Stage III Rectal Cancer using Oxaliplatin and Capecitabine	<i>Dose banding added; Protocol title, Eligibility and Treatment updated</i>	<i>Dose banding added</i>	---
GIRAJFFOX	Adjuvant or Neoadjuvant Combination Chemotherapy Treatment for Stage III Rectal Cancer using Oxaliplatin, Fluorouracil, and Leucovorin	<i>Dose banding added; Protocol title, Eligibility and Treatment updated</i>	<i>Fluorouracil dose banding table updated</i>	---
GIRCAP	Adjuvant Therapy for Stage II and III Rectal Cancer using Capecitabine in Patients Previously Treated with Preoperative Radiation Therapy Alone	<i>Dose banding added</i>	<i>Dose banding added; Treatment clarified</i>	---
GIRCRT	Combined Modality Adjuvant Therapy for High-Risk Rectal Carcinoma using Capecitabine and Radiation Therapy	<i>Note added: new patients to start on GIRCRT</i>	---	---
GIRINFRT	Combined Modality Adjuvant Therapy for High-Risk Rectal Carcinoma using Capecitabine, Infusional Fluorouracil and Radiation Therapy	<i>Dose banding added; Exclusions and Treatment clarified</i>	<i>Dose banding added; Treatment clarified</i>	---
HN Head and Neck				
HNAVCAP	Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck with Capecitabine	<i>Dose banding added; Eligibility clarified; Contact Physician and Tests updated</i>	<i>Dose banding added; Tests clarified</i>	---
HNNAVCAP	Treatment of Recurrent or Metastatic Nasopharyngeal Cancer with Capecitabin	<i>Dose banding added; Eligibility and Tests clarified; Contact Physician updated</i>	<i>Dose banding added; Tests clarified</i>	---
LU Lung				
LUVALE	Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Alectinib	<i>Contact Physician, Exclusions, Tests, Treatment and Dose Modifications updated</i>	<i>Tests updated</i>	---
LUAVBRI	First-Line Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Brigatinib	<i>Contact Physician and Exclusions updated</i>	---	---

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
LUAVCRIZ	Second-Line Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Crizotinib	<i>Tests updated</i>	---	---
LUAVCRIZF	First-Line Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Crizotinib	<i>Contact Physician and Exclusions updated</i>	---	---
LUAVLOR	Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Lorlatinib	<i>Contact Physician and Exclusions updated; Tests clarified</i>	---	---
LY Lymphoma				
LYBENDO	Treatment of Rituximab-Refractory Follicular Lymphoma with Bendamustine in Combination with Obinutuzumab	<i>Filgrastim note added</i>	---	---
LYCLLIV	Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma using Ibrutinib and Venetoclax	<i>Baseline labs updated</i>	---	---
LYDARCBDF	Treatment of Previously Untreated Light Chain Amyloidosis and Not Eligible for Stem Cell Transplant using Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone	<i>Filgrastim note and SCDRUGRX hyperlink added</i>	---	---
LYDHAPR	Treatment of Lymphoma with Dexamethasone, Cytarabine, Platinum and Rituximab	<i>Filgrastim note added</i>	---	---
LYGDP	Treatment of Lymphoma with Gemcitabine, Dexamethasone and Platinum	<i>Filgrastim note added</i>	---	---
LYGDPO	Treatment of Rituximab-Refractory Follicular Lymphoma with Gemcitabine, Dexamethasone, Platinum and Obinutuzumab	<i>Filgrastim note added</i>	---	---
LYGDPR	Treatment of Lymphoma with Gemcitabine, Dexamethasone and Platinum with Rituximab	<i>Filgrastim note added</i>	---	---
LYGEMOXPEG	Treatment of Newly Diagnosed or Relapsed/Refractory Natural Killer or T-Cell Lymphoma using Gemcitabine, Oxaliplatin and Pegaspargase	<i>Filgrastim note and SCDRUGRX hyperlink added</i>	---	---
LYHDMRTEM	Treatment of Primary and Secondary CNS Lymphoma with High-Dose Methotrexate, Rituximab and Temozolomide	<i>Dose banding added; Treatment clarified</i>	<i>Dose banding added; Treatment clarified</i>	---
LYOBCHLOR	Treatment of Previously Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma with Obinutuzumab and Chlorambucil	<i>Filgrastim note added</i>	---	---
LYPRA	Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) with Pralatrexate	<i>Filgrastim note added</i>	---	---

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
LYTEM	Treatment of Relapsed CNS Lymphoma using Temozolomide	<i>Dose banding added</i>	<i>Dose banding added; Treatment clarified</i>	---
ULYWMZANU	Treatment of Waldenström Macroglobulinemia or Lymphoplasmacytic Lymphoma (LPL) using Zanubrutinib	<i>Notes updated</i>	---	---
SM Skin & Melanoma				
SMAVTMZ	Palliative Therapy for Malignant Melanoma with Brain Metastases using Temozolomide	<i>Dose banding added; Tests and Treatment clarified</i>	<i>Dose banding added; Tests and Treatment clarified</i>	---

Resources and Contact Information

Resource	Phone	Email / Toll Free / Fax
Systemic Therapy Update: www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update		
Systemic Therapy Update Editor	604-877-6000 x 672649	bulletin@bccancer.bc.ca
Oncology Drug Information	604-877-6275	druginfo@bccancer.bc.ca
Cancer Drug Manual Editor	250-519-5500 x 693742	nbadry@bccancer.bc.ca
Pharmacy Oncology Certification	250-712-3900 x 686820	rxchemocert@bccancer.bc.ca
CAP – Compassionate Access Program	604-877-6277	cap_bcca@bccancer.bc.ca fax 604-708-2026
OSCAR – Online System for Cancer Drugs Adjudication and Reimbursement	888-355-0355	oscar@bccancer.bc.ca fax 604-708-2051
Library/Cancer Information	604-675-8003	toll free 888-675-8001 x 8003 requests@bccancer.bc.ca
Library Document Delivery	604-675-8002	requests@bccancer.bc.ca
Pharmacy Professional Practice	604-877-6000 x 672247	mclin@bccancer.bc.ca
Professional Practice, Nursing	604-877-6000 x 672623	BCCancerPPNAdmin@phsa.ca
Provincial Systemic Therapy Network	604-877-6000 x 672247	ProvincialSystemicOffice@bccancer.bc.ca
BC Cancer – Abbotsford	604-851-4710	toll free 877-547-3777
BC Cancer – Kelowna	250-712-3900	toll free 888-563-7773
BC Cancer – Prince George	250-645-7300	toll free 855-775-7300
BC Cancer – Surrey	604-930-2098	toll free 800-523-2885
BC Cancer – Vancouver	604-877-6000	toll free 800-663-3333
BC Cancer – Victoria	250-519-5500	toll free 800-670-3322
Community Oncology Network (CON) sites: To update your contact information, please contact: bulletin@bccancer.bc.ca		

Editorial Review Board

Anne Dar Santos, BScPharm, PharmD (Editor)
 Jelena Mucovic, BScPharm (Assistant Editor)
 Mario de Lemos, PharmD, MSc(Oncol)
 Jeevan Dosanjh, RN, BScN, MN

Alina Gerrie, MD, MPH, FRCPC
 Alison Pow, BScPharm
 Yuna Jang, RN